Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior GuidancePreviously Provided FY 2025 Adjusted ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...